Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
